Targeting HMGB1 ameliorates cardiac fibrosis through restoring TLR2-mediated autophagy suppression in myocardial fibroblasts

International Journal of Cardiology

Volumn 267, Issue , 2018, Pages 156-162

  Wu, Ri Na ^a,b   Yu, Tian Yu ^a   Zhou, Ji Chao ^c   Li, Meng ^b   Gao, Hui Kuan ^a   Zhao, Can ^a   Dong, Rui Qing ^d   Peng, Dian ^c   Hu, Zhuo Wei ^c   Zhang, Xiao Wei ^c   Wu, Yong Quan ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b BAOTOU CENTRAL HOSPITAL   (China)

^c INSTITUTE OF MATERIA MEDICA   (China)

^d NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Autophagic flux; DAMPs; Glycyrrhizic acid; Heart remodeling; p62

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; GLYCYRRHIZIC ACID; HIGH MOBILITY GROUP B1 PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; SEQUESTOSOME 1; TOLL LIKE RECEPTOR 2; ANTIINFLAMMATORY AGENT; HMGB1 PROTEIN, MOUSE; TLR2 PROTEIN, MOUSE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; ECHOCARDIOGRAPHY; ENZYME INHIBITION; HEART FIBROBLAST; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE FIBROSIS; IMMUNOBLOTTING; IMMUNOFLUORESCENCE TEST; IMMUNOPRECIPITATION; INFLAMMATION; INFLAMMATORY CELL; MALE; MOUSE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN EXPRESSION LEVEL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIAC MUSCLE; DISEASE MODEL; DRUG EFFECT; FIBROBLAST; FIBROSIS; HEART DISEASE; METABOLISM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; AUTOPHAGY; DISEASE MODELS, ANIMAL; FIBROBLASTS; FIBROSIS; GLYCYRRHIZIC ACID; HEART DISEASES; HMGB1 PROTEIN; MICE; MYOCARDIUM; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 2;

EID: 85046137661     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2018.04.103     Document Type: Article

References (43)

1. Vilahur, G., Juan-Babot, O., Pena, E., et al. Molecular and cellular mechanisms involved in cardiac remodeling after acute myocardial infarction. J. Mol. Cell. Cardiol. 50:3 (2011), 522–533.
2. Lin, C., Zhang, M., Zhang, Y., et al. Helix B surface peptide attenuates diabetic cardiomyopathy via AMPK-dependent autophagy. Biochem. Biophys. Res. Commun. 482:4 (2017), 665–671.
3. Ma, Y., Zhang, X., Bao, H., et al. Toll-like receptor (TLR) 2 and TLR4 differentially regulate doxorubicin induced cardiomyopathy in mice. PLoS One, 7(7), 2012, e40763.
4. Swynghedauw, B., Molecular mechanisms of myocardial remodeling. Physiol. Rev. 79:1 (1999), 215–262.
5. Delcayre, C., Swynghedauw, B., Molecular mechanisms of myocardial remodeling. The role of aldosterone. J. Mol. Cell. Cardiol. 34:12 (2002), 1577–1584.
6. Segura, A.M., Frazier, O.H., Buja, L.M., Fibrosis and heart failure. Heart Fail. Rev. 19:2 (2014), 173–185.
7. Kong, P., Christia, P., Frangogiannis, N.G., The pathogenesis of cardiac fibrosis. Cell. Mol. Life Sci. 71:4 (2014), 549–574.
8. Travers, J.G., Kamal, F.A., Robbins, J., et al. Cardiac fibrosis: the fibroblast awakens. Circ. Res. 118:6 (2016), 1021–1040.
9. Yanai, H., Taniguchi, T., Nucleic acid sensing and beyond: virtues and vices of high-mobility group box 1. J. Intern. Med. 276:5 (2014), 444–453.
10. Tang, D., Kang, R., Livesey, K.M., et al. Endogenous HMGB1 regulates autophagy. J. Cell Biol. 190:5 (2010), 881–892.
11. Wang, W.K., Wang, B., Lu, Q.H., et al. Inhibition of high-mobility group box 1 improves myocardial fibrosis and dysfunction in diabetic cardiomyopathy. Int. J. Cardiol. 172:1 (2014), 202–212.
12. Lotze, M.T., Tracey, K.J., High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat. Rev. Immunol. 5:4 (2005), 331–342.
13. Kang, N., Hai, Y., Yang, J., et al. Hyperbaric oxygen intervention reduces secondary spinal cord injury in rats via regulation of HMGB1/TLR4/NF-kappaB signaling pathway. Int. J. Clin. Exp. Pathol. 8:2 (2015), 1141–1153.
14. Wang, J., He, G.Z., Wang, Y.K., et al. TLR4-HMGB1-, MyD88- and TRIF-dependent signaling in mouse intestinal ischemia/reperfusion injury. World J. Gastroenterol. 21:27 (2015), 8314–8325.
15. Wang, F.C., Pei, J.X., Zhu, J., et al. Overexpression of HMGB1 A-box reduced lipopolysaccharide-induced intestinal inflammation via HMGB1/TLR4 signaling in vitro. World J. Gastroenterol. 21:25 (2015), 7764–7776.
16. Levine, B., Kroemer, G., Autophagy in the pathogenesis of disease. Cell 132:1 (2008), 27–42.
17. Nakai, A., Yamaguchi, O., Takeda, T., et al. The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress. Nat. Med. 13:5 (2007), 619–624.
18. Taneike, M., Yamaguchi, O., Nakai, A., et al. Inhibition of autophagy in the heart induces age-related cardiomyopathy. Autophagy 6:5 (2010), 600–606.
19. Przyklenk, K., Dong, Y., Undyala, V.V., et al. Autophagy as a therapeutic target for ischaemia/reperfusion injury? Concepts, controversies, and challenges. Cardiovasc. Res. 94:2 (2012), 197–205.
20. Nishida, K., Otsu, K., Autophagy during cardiac remodeling. J. Mol. Cell. Cardiol. 95 (2016), 11–18.
21. Sciarretta, S., Yee, D., Shenoy, V., et al. The importance of autophagy in cardioprotection. High Blood Press. Cardiovasc. Prev. 21:1 (2014), 21–28.
22. Dong, R.Q., Wang, Z.F., Zhao, C., et al. Toll-like receptor 4 knockout protects against isoproterenol-induced cardiac fibrosis: the role of autophagy. J. Cardiovasc. Pharmacol. Ther. 20:1 (2015), 84–92.
23. Ryu, Y., Jin, L., Kee, H.J., et al. Gallic acid prevents isoproterenol-induced cardiac hypertrophy and fibrosis through regulation of JNK2 signaling and Smad3 binding activity. Sci. Rep., 6, 2016, 34790.
24. Zhai, C.L., Zhang, M.Q., Zhang, Y., et al. Glycyrrhizin protects rat heart against ischemia-reperfusion injury through blockade of HMGB1-dependent phospho-JNK/Bax pathway. Acta Pharmacol. Sin. 33:12 (2012), 1477–1487.
25. Respress, J.L., Wehrens, X.H., Transthoracic echocardiography in mice. J. Vis. Exp.(39), 2010.
26. Qian, L., Huang, Y., Spencer, C.I., et al. In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. Nature(485), 2012, 593–598.
27. Watanabe, Y., Tanaka, M., p62/SQSTM1 in autophagic clearance of a non-ubiquitylated substrate. J. Cell Sci. 124:Pt 16 (2011), 2692–2701.
28. Hua, F., Li, K., Yu, J.J., et al. TRB3 links insulin/IGF to tumour promotion by interacting with p62 and impeding autophagic/proteasomal degradations. Nat. Commun., 6, 2015, 7951.
29. Musumeci, D., Roviello, G.N., Montesarchio, D., An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies. Pharmacol. Ther. 141:3 (2014), 347–357.
30. Liang, B., Guo, X.L., Jin, J., et al. Glycyrrhizic acid inhibits apoptosis and fibrosis in carbon-tetrachloride-induced rat liver injury. World J. Gastroenterol. 21:17 (2015), 5271–5280.
31. Okuma, Y., Liu, K., Wake, H., et al. Glycyrrhizin inhibits traumatic brain injury by reducing HMGB1-RAGE interaction. Neuropharmacology 85 (2014), 18–26.
32. Sun, X., Tang, D., HMGB1-dependent and -independent autophagy. Autophagy 10:10 (2014), 1873–1876.
33. Ouyang, F., Huang, H., Zhang, M., et al. HMGB1 induces apoptosis and EMT in association with increased autophagy following H/R injury in cardiomyocytes. Int. J. Mol. Med. 37:3 (2016), 679–689.
34. de Haan, J.J., Smeets, M.B., Pasterkamp, G., et al. Danger signals in the initiation of the inflammatory response after myocardial infarction. Mediat. Inflamm., 2013, 2013, 206039.
35. Favre, J., Musette, P., Douin-Echinard, V., et al. Toll-like receptors 2-deficient mice are protected against postischemic coronary endothelial dysfunction. Arterioscler. Thromb. Vasc. Biol. 27:5 (2007), 1064–1071.
36. Oyama, J., Blais, C. Jr., Liu, X., et al. Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation 109:6 (2004), 784–789.
37. Santiago, J.J., Dangerfield, A.L., Rattan, S.G., et al. Cardiac fibroblast to myofibroblast differentiation in vivo and in vitro: expression of focal adhesion components in neonatal and adult rat ventricular myofibroblasts. Dev. Dyn. 239:6 (2010), 1573–1584.
38. Lajiness, J.D., Conway, S.J., Origin, development, and differentiation of cardiac fibroblasts. J. Mol. Cell. Cardiol. 70 (2014), 2–8.
39. Drobic, V., Cunnington, R.H., Bedosky, K.M., et al. Differential and combined effects of cardiotrophin-1 and TGF-beta1 on cardiac myofibroblast proliferation and contraction. Am. J. Physiol. Heart Circ. Physiol. 293:2 (2007), H1053–1064.
40. Petrov, V.V., Fagard, R.H., Lijnen, P.J., Stimulation of collagen production by transforming growth factor-beta1 during differentiation of cardiac fibroblasts to myofibroblasts. Hypertension 39:2 (2002), 258–263.
41. Frangogiannis, N.G., Fibroblasts and the extracellular matrix in right ventricular disease. Cardiovasc. Res. 113:12 (2017), 1453–1464.
42. Mizushima, N., Yoshimori, T., Levine, B., Methods in mammalian autophagy research. Cell 140:3 (2010), 313–326.
43. Puissant, A., Fenouille, N., Auberger, P., When autophagy meets cancer through p62/SQSTM1. Am. J. Cancer Res. 2:4 (2012), 397–413.